Modulating extracellular TCR-CD3 interactions to identify new melanoma immunotherapy targets

调节细胞外 TCR-CD3 相互作用以确定新的黑色素瘤免疫治疗靶点

基本信息

  • 批准号:
    10290708
  • 负责人:
  • 金额:
    $ 23.77万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-06-01 至 2023-05-31
  • 项目状态:
    已结题

项目摘要

ABSTRACT Melanoma is one of the deadliest and aggressive form of skin cancer. Main treatment options in metastatic melanoma involve T cell immunotherapy using checkpoint blockade (anti-PD-1, anti-CTLA-4 and others) or adoptive T cell therapy (ACT) with modified patient T cells. Although, durable response is only observed in a fraction of patients. Further progress can be made by studying and targeting different T cell signaling pathways. One such pathway is the T cell receptor (TCR) signaling pathway. T cell recognition of antigen by the TCR and the resulting proximal signaling through the surrounding CD3 subunits are key steps in the initiation of tumor-killing. Identification of the specific extracellular contacts between the TCR and CD3 subunits gives precise guidance for immunotherapeutic strategies that modulate T-cell immunity by targeting signaling through the TCR-CD3 complex. Previous studies that targeted the antigen binding site for enhancing T-cell responses to tumor antigens often lead to off-target effects and toxicity. Based on our recent TCR-CD3 structure, we mutated specific CD3 interacting TCR-residues that resulted in different T cell cytokine responses. Our hypothesis is that by modulating TCR-CD3 interactions in specific ways, immune-mediated cytotoxicity to tumor antigens can be increased without losing specificity for the cancer antigen. To test our hypothesis, in Aim 1, an in vitro retroviral TCR display method and a novel CD3-tetramer assay will be used to mutate specific TCR-residues and identify TCRs that interact with CD3 with increased affinity, resulting in T cells that mediate more effective functionality. In Aim 2, a structure-based TCR design will be used to identify TCR mutants with enhanced CD3 binding ability in silico. In both instances, identified mutations will be introduced into gp100-specific TCRs and their in vitro/in vivo tumor killing efficacy will be analyzed to validate the anti-tumor potential of new TCRs with the goal of developing new wave of effective T cell therapies against melanoma.
摘要 黑色素瘤是最致命和侵袭性最强的皮肤癌之一。转移性肿瘤的主要治疗选择 黑色素瘤涉及T细胞免疫治疗,使用检查点阻断(抗PD-1、抗CTLA-4等)或 采用改良的患者T细胞进行过继T细胞治疗(ACT)。尽管,持久的反应只有在 病人的一部分。通过研究和针对不同的T细胞信号转导可以取得进一步的进展 小路。其中一个途径是T细胞受体(TCR)信号通路。T细胞对抗原的识别 TCR和由此产生的通过周围CD3亚单位的近端信号是 启动肿瘤杀灭。TCR和CD3亚基之间特异性胞外接触的鉴定 为通过靶向信号调节T细胞免疫的免疫治疗策略提供准确的指导 通过TCR-CD3复合体。先前针对抗原结合部位增强T细胞的研究 对肿瘤抗原的反应往往会导致非靶点效应和毒性。根据我们最新的TCR-CD3 结构,我们突变了特定的CD3与TCR残基相互作用,从而产生了不同的T细胞细胞因子 回应。我们的假设是,通过以特定方式调节TCR-CD3相互作用,免疫介导的 在不丧失肿瘤抗原特异性的情况下,可以增加对肿瘤抗原的细胞毒性。测试我们的 假设,在目标1中,将使用体外逆转录病毒TCR展示方法和新的CD3-四聚体分析来 突变特定的TCR残基,并鉴定与CD3相互作用的TCR,亲和力增强,导致T细胞 调节更有效功能的细胞。在目标2中,将使用基于结构的TCR设计来识别 在硅胶中CD3结合能力增强的TCR突变体。在这两种情况下,已识别的突变都将是 将其导入gp100特异性TCR,并对其体外/体内肿瘤杀伤效果进行分析以验证 以开发新一波有效的T细胞疗法为目标的新型TCR的抗肿瘤潜力 黑色素瘤。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Aswin Natarajan其他文献

Aswin Natarajan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Aswin Natarajan', 18)}}的其他基金

Modulating extracellular TCR-CD3 interactions to identify new melanoma immunotherapy targets
调节细胞外 TCR-CD3 相互作用以确定新的黑色素瘤免疫治疗靶点
  • 批准号:
    10406370
  • 财政年份:
    2021
  • 资助金额:
    $ 23.77万
  • 项目类别:

相似海外基金

Double Incorporation of Non-Canonical Amino Acids in an Animal and its Application for Precise and Independent Optical Control of Two Target Genes
动物体内非规范氨基酸的双重掺入及其在两个靶基因精确独立光学控制中的应用
  • 批准号:
    BB/Y006380/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.77万
  • 项目类别:
    Research Grant
Quantifying L-amino acids in Ryugu to constrain the source of L-amino acids in life on Earth
量化 Ryugu 中的 L-氨基酸以限制地球生命中 L-氨基酸的来源
  • 批准号:
    24K17112
  • 财政年份:
    2024
  • 资助金额:
    $ 23.77万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Molecular recognition and enantioselective reaction of amino acids
氨基酸的分子识别和对映选择性反应
  • 批准号:
    23K04668
  • 财政年份:
    2023
  • 资助金额:
    $ 23.77万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Basic research toward therapeutic strategies for stress-induced chronic pain with non-natural amino acids
非天然氨基酸治疗应激性慢性疼痛策略的基础研究
  • 批准号:
    23K06918
  • 财政年份:
    2023
  • 资助金额:
    $ 23.77万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular mechanisms how arrestins that modulate localization of glucose transporters are phosphorylated in response to amino acids
调节葡萄糖转运蛋白定位的抑制蛋白如何响应氨基酸而被磷酸化的分子机制
  • 批准号:
    23K05758
  • 财政年份:
    2023
  • 资助金额:
    $ 23.77万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Design and Synthesis of Fluorescent Amino Acids: Novel Tools for Biological Imaging
荧光氨基酸的设计与合成:生物成像的新工具
  • 批准号:
    2888395
  • 财政年份:
    2023
  • 资助金额:
    $ 23.77万
  • 项目类别:
    Studentship
Collaborative Research: RUI: Elucidating Design Rules for non-NRPS Incorporation of Amino Acids on Polyketide Scaffolds
合作研究:RUI:阐明聚酮化合物支架上非 NRPS 氨基酸掺入的设计规则
  • 批准号:
    2300890
  • 财政年份:
    2023
  • 资助金额:
    $ 23.77万
  • 项目类别:
    Continuing Grant
Structurally engineered N-acyl amino acids for the treatment of NASH
用于治疗 NASH 的结构工程 N-酰基氨基酸
  • 批准号:
    10761044
  • 财政年份:
    2023
  • 资助金额:
    $ 23.77万
  • 项目类别:
Lifestyle, branched-chain amino acids, and cardiovascular risk factors: a randomized trial
生活方式、支链氨基酸和心血管危险因素:一项随机试验
  • 批准号:
    10728925
  • 财政年份:
    2023
  • 资助金额:
    $ 23.77万
  • 项目类别:
Single-molecule protein sequencing by barcoding of N-terminal amino acids
通过 N 端氨基酸条形码进行单分子蛋白质测序
  • 批准号:
    10757309
  • 财政年份:
    2023
  • 资助金额:
    $ 23.77万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了